Lumira Ventures
Toronto, Ontario
Investment Thesis
Leading North American life sciences VC identifying best-in-class companies across the development continuum in overlooked geographies. Focus on therapeutic products and medical devices targeting cancer, cardiovascular, CNS, immunology, and autoimmune indications with high unmet clinical need, prioritizing transformative approaches that break treatment paradigms, enable inclusivity, improve outcomes, and reduce healthcare costs.
Focus Areas
Investment Stage
Multi-Stage
Sectors
Investment Signals
GeographyNorth America
ProvincesON, BC, QC
RoleBoth
Impact MandateYes
Business Modelsdeep-tech, hardware
Sample Portfolio Companies
HistoSonics (2025 NVCA Startup Innovator, Fast Company #1)
COUR
enGene
Transposon
Sound Blade Medical
Nervonik
Contraline
Management Team
7
7 senior partners, 10 investment professionals, hundreds of years experience
What Makes Us Unique
Market-leading performance: distributed returns in 19 of past 20 years. Six exits exceeding $1B in past six years. Deep domain expertise enabling thematic research.
AUM & Sources
Est. US$500M
Assets under management (estimated)
Sources
No public sources found.
Raising from Canadian VCs?Get AI-matched to your top investors in seconds.
Find My Investors →Similar Funds
See incorrect information?
Help us keep this directory accurate and up to date.